![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
December 19, 2023
This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
December 19, 2023
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
December 19, 2023
In an annual evaluation, 46 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
December 19, 2023
These four lung cancer treatment trials are all open and enrolling patients
August 25, 2023
NCORP Annual Meeting updates; data gaps and social determinants of health; the NCI Clinical Trials Innovation Unit
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy.
August 25, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 30, 2023
The Group is recognizing Dr. Forde as an exceptional physician-scientist who is making significant research contributions as a translational thoracic cancer investigator